MCID: THY029
MIFTS: 54

Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Thyroid Carcinoma

MalaCards integrated aliases for Thyroid Carcinoma:

Name: Thyroid Carcinoma 58 29 54 6 17 70
Thyroid Cancer 36 29 54 42
Malignant Neoplasm of Thyroid 70
Thyroid Neoplasm 70

Characteristics:

Orphanet epidemiological data:

58
thyroid carcinoma
Prevalence: 6-9/10000 (Europe),1-5/10000 (United States),1-9/100000 (Worldwide),1-5/10000 (Worldwide); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

KEGG 36 H00032
UMLS via Orphanet 71 C0549473
Orphanet 58 ORPHA100088
UMLS 70 C0007115 C0040136 C0549473

Summaries for Thyroid Carcinoma

MedlinePlus : 42 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Carcinoma, also known as thyroid cancer, is related to thyroid carcinoma, familial medullary and thyroid gland anaplastic carcinoma, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Thyroid Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Sevoflurane and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and pituitary.

KEGG : 36 Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer- related deaths each year. More than 95% of thyroid carcinomas are derived from follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, respectively) to the extremely aggressive undifferentiated carcinoma (UC). Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. The most distinctive molecular features of FTC are the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-PPAR{gamma} rearrangements. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma.

Related Diseases for Thyroid Carcinoma

Diseases related to Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1095)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 33.3 RET NKX2-1 MALAT1 BRAF
2 thyroid gland anaplastic carcinoma 33.0 TSHR RET NKX2-1 BRAF
3 differentiated thyroid carcinoma 32.9 TSHR RET NKX2-1 BRAF
4 thyroid gland follicular carcinoma 32.7 TSHR RET NKX2-1 BRAF
5 thyroid cancer, nonmedullary, 1 32.6 PVT1 PTCSC3 NKX2-1 NEAT1 MALAT1 HOTAIR
6 papillary carcinoma 32.2 TSHR RET NKX2-1 BRAF
7 goiter 32.1 TSHR RET NKX2-1
8 thyroid tumor 32.0 RET BRAF
9 nodular goiter 31.8 TSHR RET BRAF
10 hypothyroidism 31.6 TSHR RET NKX2-1 BRAF
11 follicular adenoma 31.6 TSHR RET NKX2-1 BRAF
12 thyroid gland cancer 31.5 TSHR RET NKX2-1 BRAF
13 thyroid gland disease 31.5 TSHR RET NKX2-1
14 hashimoto thyroiditis 31.4 TSHR RET BRAF
15 papillary thyroid microcarcinoma 31.4 TSHR NKX2-1 BRAF
16 struma ovarii 31.2 TSHR RET NKX2-1 BRAF
17 malignant struma ovarii 31.0 RET NKX2-1
18 ovarian germ cell teratoma 31.0 RET NKX2-1
19 adenocarcinoma 30.8 RET NKX2-1 MALAT1 H19 BRAF
20 thyroid gland papillary carcinoma 30.7 GAS5 BRAF
21 pituitary adenoma 30.7 MALAT1 HOTAIR H19
22 benign struma ovarii 30.4 TSHR RET NKX2-1 BRAF
23 b-cell lymphoma 30.2 PVT1 MALAT1 HOTAIR GAS5
24 athyreosis 30.1 TSHR NKX2-1
25 tall cell variant papillary carcinoma 30.1 RET NKX2-1 BRAF
26 spitzoid melanoma 30.1 RET BRAF
27 retinitis pigmentosa 11 30.0 UCA1 PVT1 NEAT1 HOTAIR
28 gastric adenocarcinoma 30.0 NEAT1 HOTAIR H19 BRAF
29 malignant pleural mesothelioma 29.9 PVT1 NKX2-1 GAS5
30 squamous cell carcinoma 29.9 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
31 small cell cancer of the lung 29.9 NKX2-1 MALAT1 HOTAIR
32 laryngeal squamous cell carcinoma 29.8 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
33 leukemia, chronic myeloid 29.8 UCA1 HOTAIR H19 BRAF
34 kidney cancer 29.7 PVT1 MALAT1 HOTAIR H19 GAS5
35 leukemia 29.7 NEAT1 MLF1 HOTAIR GAS5 CDKN2B-AS1 BRAF
36 lung cancer susceptibility 3 29.7 NKX2-1 MALAT1 HOTAIR H19 GAS5 CASC2
37 glioblastoma 29.7 MALAT1 HOTAIR H19 GAS5 BRAF
38 oral squamous cell carcinoma 29.6 UCA1 NEAT1 MALAT1 HOTAIR H19
39 melanoma 29.5 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
40 leukemia, acute myeloid 29.2 UCA1 MLF1 MALAT1 HOTAIR CDKN2B-AS1
41 endometrial cancer 29.1 UCA1 RET NKX2-1 NEAT1 HOTAIR H19
42 myeloma, multiple 29.1 UCA1 PVT1 NKX2-1 MALAT1 HOTAIR H19
43 esophageal cancer 29.0 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
44 pancreatic ductal adenocarcinoma 29.0 UCA1 PVT1 MALAT1 HOTAIR H19 AFAP1-AS1
45 tongue squamous cell carcinoma 28.9 UCA1 MALAT1 AFAP1-AS1
46 renal cell carcinoma, nonpapillary 28.9 UCA1 RET PVT1 PANDAR NKX2-1 MALAT1
47 cholangiocarcinoma 28.9 UCA1 PANDAR NEAT1 MALAT1 H19 BRAF
48 high grade glioma 28.5 PVT1 NEAT1 MALAT1 HOTAIR H19 GAS5
49 osteogenic sarcoma 28.4 UCA1 PVT1 PANDAR NEAT1 MALAT1 HOTAIR
50 glioma 28.3 UCA1 PVT1 PTCSC3 NEAT1 MALAT1 HOTAIR

Comorbidity relations with Thyroid Carcinoma via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Carcinoma:



Diseases related to Thyroid Carcinoma

Symptoms & Phenotypes for Thyroid Carcinoma

UMLS symptoms related to Thyroid Carcinoma:


tinnitus; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

Drugs & Therapeutics for Thyroid Carcinoma

Drugs for Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 274)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
8
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
9
Codeine Approved, Illicit Phase 4 76-57-3 5284371
10
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Citrate Phase 4
13 Anesthetics, Intravenous Phase 4
14 Anesthetics, General Phase 4
15 Anesthetics Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Sodium Channel Blockers Phase 4
18 Anesthetics, Local Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Analgesics Phase 4
22 Respiratory System Agents Phase 4
23 Narcotics Phase 4
24 Analgesics, Opioid Phase 4
25 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
26 Antitussive Agents Phase 4
27 Antipyretics Phase 4
28 Selenium Supplement Phase 4
29 Protective Agents Phase 4
30 Antioxidants Phase 4
31
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
32
Racepinephrine Approved Phase 3 329-65-7 838
33
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
34
Iodine Approved, Investigational Phase 3 7553-56-2 807
35
Cadexomer iodine Experimental Phase 3 94820-09-4
36 Fibrin Tissue Adhesive Phase 3
37 Adrenergic alpha-Agonists Phase 3
38 Adrenergic Agonists Phase 3
39 Adrenergic Agents Phase 3
40 Vasoconstrictor Agents Phase 3
41 Adrenergic beta-Agonists Phase 3
42 Epinephryl borate Phase 3
43 Anti-Asthmatic Agents Phase 3
44 Mydriatics Phase 3
45 Sympathomimetics Phase 3
46 Bronchodilator Agents Phase 3
47 Hemostatics Phase 3
48 Coagulants Phase 3
49 Hormones Phase 3
50
Apatinib Phase 3 811803-05-1

Interventional clinical trials:

(show top 50) (show all 513)
# Name Status NCT ID Phase Drugs
1 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
2 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
3 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
4 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
5 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
6 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
7 Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study) Recruiting NCT04574947 Phase 4 Intravenous lidocaine;Intravenous placebo
8 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
9 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Active, not recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
10 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Active, not recruiting NCT03573960 Phase 4 Lenvatinib
11 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
12 Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma. Not yet recruiting NCT04683575 Phase 4 Selenium Yeast;Placebo
13 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Terminated NCT02946918 Phase 4 Levothyroxine
14 Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Unknown status NCT02418247 Phase 2, Phase 3 I131;I123
15 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
16 Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq Unknown status NCT00115895 Phase 3 Radioactive iodine
17 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Unknown status NCT01149161 Phase 2, Phase 3
18 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
19 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
20 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
21 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
22 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
23 Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
24 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
25 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
26 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
27 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
29 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
30 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
31 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Completed NCT00704730 Phase 3 XL184;Placebo
32 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
33 A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
34 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
35 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
36 Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy Recruiting NCT04290663 Phase 3 Systematic RAI-treatment
37 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
39 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Active, not recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
40 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
41 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
42 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
43 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT01398085 Phase 2, Phase 3
44 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
45 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
46 A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. Not yet recruiting NCT04760288 Phase 3 Pralsetinib;Cabozantinib;Vandetanib
47 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
48 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer Terminated NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
49 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
50 Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Unknown status NCT03565536 Phase 2 Nexavar

Search NIH Clinical Center for Thyroid Carcinoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Interferon Alfa-2b
lenvatinib
levothyroxine
Levothyroxine Sodium
liothyronine
liothyronine sodium
sorafenib
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR
thyrotropin alfa
Vandetanib

Genetic Tests for Thyroid Carcinoma

Genetic tests related to Thyroid Carcinoma:

# Genetic test Affiliating Genes
1 Thyroid Cancer 29
2 Thyroid Carcinoma 29

Anatomical Context for Thyroid Carcinoma

MalaCards organs/tissues related to Thyroid Carcinoma:

40
Thyroid, Lymph Node, Pituitary, Endothelial, Bone, Trachea, Salivary Gland

Publications for Thyroid Carcinoma

Articles related to Thyroid Carcinoma:

(show top 50) (show all 39098)
# Title Authors PMID Year
1
High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. 61 6
23416954 2013
2
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 61 6
16778204 2006
3
Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. 6 61
11389085 2001
4
Effect of ¹³¹I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer. 42 61
33568620 2021
5
Mass spectrometry - based imaging techniques for iodine-127 and iodine-129 detection and localization in the brown alga Laminaria digitata. 42
33631504 2021
6
Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma. 42
33578562 2021
7
INSL3 has tumor-promoting activity in thyroid cancer. 61 54
19950223 2010
8
Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. 54 61
20075119 2010
9
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. 61 54
19898969 2010
10
Targeted therapy for thyroid cancer: An updated review of investigational agents. 54 61
20496261 2010
11
The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. 61 54
20200941 2010
12
Cytokines, thyroid diseases and thyroid cancer. 61 54
20381375 2010
13
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. 61 54
19897009 2010
14
Diagnostic utility of galectin-3 in thyroid cancer. 61 54
20363921 2010
15
Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. 61 54
20138958 2010
16
Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. 54 61
20332215 2010
17
Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. 54 61
20392995 2010
18
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? 61 54
20464711 2010
19
Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. 54 61
19636213 2010
20
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. 61 54
20332457 2010
21
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. 54 61
19913280 2010
22
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 54 61
20127563 2010
23
Small (<10 mm) thyroid nodules; how aggressively should they be managed? 54 61
20164665 2010
24
Standard and emerging therapies for metastatic differentiated thyroid cancer. 61 54
20142332 2010
25
Is there any venous gradient in serum thyroglobulin levels in patients with differentiated thyroid cancer? 54 61
20353278 2010
26
Selectively targeting mutant BRAF in thyroid cancer. 61 54
20056810 2010
27
The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women. 54 61
20151763 2010
28
Recent advances in the research and development of B-Raf inhibitors. 54 61
20345352 2010
29
Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? 61 54
20017617 2010
30
Targeting the RET pathway in thyroid cancer. 61 54
19934298 2009
31
Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. 61 54
19958935 2009
32
Clinical inquiries. What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer? 61 54
19961815 2009
33
[Usefulness of the determination of thyroglobulin in lymph node aspirates of patients with papillary thyroid carcinoma and positive antithyroglobulin antibodies]. 54 61
20096208 2009
34
F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. 61 54
19851169 2009
35
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. 54 61
19878585 2009
36
Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels. 61 54
20083851 2009
37
Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer. 54 61
19910901 2009
38
Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence. 54 61
19769825 2009
39
Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence. 54 61
19607742 2009
40
Significance of marginally elevated calcitonin levels in micromedullary thyroid cancer. 61 54
19636626 2009
41
Radioiodine ablation: when and how. 61 54
19910900 2009
42
Molecularly targeted therapies for thyroid cancers. 61 54
19546052 2009
43
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. 61 54
19574281 2009
44
A microfluidic biosensor based on competitive protein adsorption for thyroglobulin detection. 61 54
19577460 2009
45
Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. 61 54
19678746 2009
46
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. 61 54
19551443 2009
47
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. 61 54
19524134 2009
48
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. 61 54
19530676 2009
49
Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. 61 54
18806930 2009
50
Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. 61 54
19652218 2009

Variations for Thyroid Carcinoma

ClinVar genetic disease variations for Thyroid Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RET NM_020975.6(RET):c.1900T>C (p.Cys634Arg) SNV Pathogenic 13917 rs75076352 GRCh37: 10:43609948-43609948
GRCh38: 10:43114500-43114500

Copy number variations for Thyroid Carcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 75266 13 18400000 72100000 Loss Thyroid cancer
2 80538 13 93800000 114142980 Loss Thyroid cancer
3 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
4 111285 17 35400000 68400000 Gain Thyroid cancer
5 120295 18 23300000 71300000 Loss Thyroid cancer
6 150420 20 1 27100000 Amplification Thyroid cancer
7 151957 20 27100000 62435964 Amplification Thyroid cancer
8 153452 20 37100000 62435964 Gain Thyroid cancer
9 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
10 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
11 191662 5 1 45800000 Amplification Thyroid cancer
12 200481 5 55800000 180857866 Gain Thyroid cancer
13 201091 5 65300000 159900000 Amplification Thyroid cancer
14 217036 7 1 158821424 Amplification Thyroid cancer
15 230743 8 1 19100000 Loss Thyroid cancer
16 236403 8 16100000 117700000 Amplification Thyroid cancer
17 236404 8 16100000 146274826 Gain Thyroid cancer
18 261707 X 24900000 59500000 Loss Thyroid cancer
19 303365 21 26028751 26066642 Deletion GABPA Thyroid cancer
20 96631 15 90931472 91045475 Amplificationlication IQGAP1 Thyroid cancer
21 48476 11 1 43400000 Gain Thyroid cancer
22 191664 5 1 45800000 Gain Thyroid cancer

Expression for Thyroid Carcinoma

Search GEO for disease gene expression data for Thyroid Carcinoma.

Pathways for Thyroid Carcinoma

Pathways related to Thyroid Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Thyroid Carcinoma

Biological processes related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 thyroid gland development GO:0030878 9.16 NKX2-1 BRAF
2 inner ear receptor cell stereocilium organization GO:0060122 8.96 TSHR SDC4
3 myeloid progenitor cell differentiation GO:0002318 8.62 MLF1 BRAF

Sources for Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....